专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US09533980B2 NOL3 is a predictor of patient outcome 有权
标题翻译： NOL3是患者预后的结果
公开(公告)号：US09533980B2
公开(公告)日：2017-01-03
申请号：US14464394
申请日：2014-08-20
申请人： Andrew Kung , David Ziegler
发明人： Andrew Kung , David Ziegler
IPC分类号： C07D417/02 , A61K31/496 , G01N33/50 , C12Q1/68 , G01N33/574 , A61K45/06
CPC分类号： C12Q1/6886 , A61K31/437 , A61K31/496 , A61K31/506 , A61K45/06 , C07D417/02 , C12Q2600/106 , C12Q2600/112 , C12Q2600/118 , C12Q2600/136 , C12Q2600/158 , G01N33/5044 , G01N33/57407 , G01N33/57484 , G01N2800/52 , G01N2800/7028 , A61K2300/00
摘要： The present invention features a method for determining the prognosis for survival of a cancer patient. Methods for measuring the level of NOL3 expression in a cancer cell-containing sample from a patient, and comparing the level of NOL3 expression in the sample to a reference level of NOL3 expression are also included. A higher level of NOL3 relative to the reference level correlates with decreased survival of the patient, and an equivalent or lower level of NOL3 relative to the reference level correlates with increased survival of the patient.
摘要翻译：本发明的特征在于确定癌症患者的存活预后的方法。还包括用于测量来自患者的含癌细胞的样品中的NOL3表达水平以及将样品中NOL3表达水平与NOL3表达的参考水平进行比较的方法。相对于参考水平的较高水平的NOL3与患者的生存率降低相关，并且相对于参考水平的等同或更低水平的NOL3与患者的增加的存活相关。

2. 发明授权

US08999661B2 Compositions for detecting cell death and methods of use thereof 有权
标题翻译：用于检测细胞死亡的组合物及其使用方法
公开(公告)号：US08999661B2
公开(公告)日：2015-04-07
申请号：US12511478
申请日：2009-07-29
申请人： Andrew Kung , Pallab Banerjee
发明人： Andrew Kung , Pallab Banerjee
IPC分类号： C12Q1/32 , G01N33/50 , C07K14/00 , C12N9/04
CPC分类号： C12Q1/32 , G01N33/5011 , G01N2510/00
摘要： The invention provides compounds and methods of their use in the detection of apoptosis and necrosis both in vitro and in vivo. Also provided are compounds and methods of their use in selective delivery of agents to cells undergoing apoptosis or necrosis. The compounds and methods are based on conjugates formed with a dehydrogenase such as lactate dehydrogenase, alcohol dehydrogenase, aldehyde dehydrogenase, and malate dehydrogenase. The compounds and methods are useful in the diagnosis and treatment of conditions characterized by apoptosis, including cancer, cardiac disease, neurologic disease including stroke, and autoimmunity. The compounds and methods offer distinct advantages over corresponding compounds and methods based on Annexin V. Also provided are methods for screening for compounds that modulate, i.e., inhibit or promote, apoptosis.
摘要翻译：本发明提供了它们用于体外和体内检测凋亡和坏死的化合物和方法。还提供了它们用于选择性递送药物至经历凋亡或坏死的细胞的化合物和方法。化合物和方法基于与脱氢酶形成的缀合物，例如乳酸脱氢酶，醇脱氢酶，醛脱氢酶和苹果酸脱氢酶。该化合物和方法可用于诊断和治疗特征为细胞凋亡的病症，包括癌症，心脏病，神经系统疾病，包括中风和自身免疫。化合物和方法相对于基于膜联蛋白V的相应化合物和方法提供明显的优点。还提供了筛选调节，即抑制或促进凋亡的化合物的方法。

3. 发明授权

US07781393B2 Methods for inhibiting tumor cell growth 有权
标题翻译：抑制肿瘤细胞生长的方法
公开(公告)号：US07781393B2
公开(公告)日：2010-08-24
申请号：US10590672
申请日：2005-02-25
申请人： Andrew Kung , Constantine S. Mitsiades , Nicholos Mitsiades
发明人： Andrew Kung , Constantine S. Mitsiades , Nicholos Mitsiades
IPC分类号： A01N61/00 , A61K39/00 , A61K35/12
CPC分类号： A61K45/06 , A61K31/519 , A61K38/10 , A61K39/395 , A61K2300/00
摘要： The invention methods using a insulin-like growth factor receptor inhibitor to inhibit tumor cell growth in a subject in need thereof.
摘要翻译：使用胰岛素样生长因子受体抑制剂抑制有需要的受试者的肿瘤细胞生长的本发明方法。

4. 发明申请

US20100179163A1 NOL3 IS A PREDICTOR OF PATIENT OUTCOME 有权
标题翻译： NOL3是患者的预测因素
公开(公告)号：US20100179163A1
公开(公告)日：2010-07-15
申请号：US12685411
申请日：2010-01-11
申请人： Andrew KUNG , David ZIEGLER
发明人： Andrew KUNG , David ZIEGLER
IPC分类号： A61K31/496 , C12Q1/68 , C07D401/14 , A61P35/00
CPC分类号： C12Q1/6886 , A61K31/437 , A61K31/496 , A61K31/506 , A61K45/06 , C07D417/02 , C12Q2600/106 , C12Q2600/112 , C12Q2600/118 , C12Q2600/136 , C12Q2600/158 , G01N33/5044 , G01N33/57407 , G01N33/57484 , G01N2800/52 , G01N2800/7028 , A61K2300/00
摘要： The present invention features a method for determining the prognosis for survival of a cancer patient. Methods for measuring the level of NOL3 expression in a cancer cell-containing sample from a patient, and comparing the level of NOL3 expression in the sample to a reference level of NOL3 expression are also included. A higher level of NOL3 relative to the reference level correlates with decreased survival of the patient, and an equivalent or lower level of NOL3 relative to the reference level correlates with increased survival of the patient.
摘要翻译：本发明的特征在于确定癌症患者的存活预后的方法。还包括用于测量来自患者的含癌细胞的样品中的NOL3表达水平以及将样品中NOL3表达水平与NOL3表达的参考水平进行比较的方法。相对于参考水平的较高水平的NOL3与患者的生存率降低相关，并且相对于参考水平的等同或更低水平的NOL3与患者的增加的存活相关。

5. 发明申请

US20090170130A1 Phosphospecific Chemokine Receptor Antibodies 有权
标题翻译：磷酸化趋化因子受体抗体
公开(公告)号：US20090170130A1
公开(公告)日：2009-07-02
申请号：US11994048
申请日：2006-06-30
申请人： Joshua Rubin , Andrew Kung
发明人： Joshua Rubin , Andrew Kung
IPC分类号： G01N33/574 , C07K16/18 , G01N33/53 , G01N33/566
CPC分类号： C07K14/7158 , A61K2039/505 , C07K16/2866
摘要： The present invention provides chemokine receptor antibodies that selectively bind to an activated form of the receptor but not to a non activated form of the receptor. In particular, the current invention provides phospho specific chemokine receptor antibodies. The antibodies can be used in several diagnostic, screening and purification methods.
摘要翻译：本发明提供趋化因子受体抗体，其选择性地结合受体的活化形式，但不与受体的非活化形式结合。特别地，本发明提供磷酸特异性趋化因子受体抗体。抗体可用于多种诊断，筛选和纯化方法。

6. 发明申请

US20070147443A1 High repetition rate visible optical parametric oscillator 有权
公开(公告)号：US20070147443A1
公开(公告)日：2007-06-28
申请号：US11318234
申请日：2005-12-23
申请人： Andrew Kung , Shining Zhu , Shih-Yu Tu , Zhida Gao
发明人： Andrew Kung , Shining Zhu , Shih-Yu Tu , Zhida Gao
IPC分类号： H01S3/10 , H01S3/091 , H01S3/08 , H01S3/092
CPC分类号： G02F1/39 , G02F1/3558 , G02F2202/20 , G02F2203/05
摘要： A tunable coherent light source includes a pump laser for generating a pump beam and an optical parametric oscillator including a crystal exhibiting an output curve for a pump beam of a defined wavelength, the output curve defining wavelengths of signal and idler outputs based on periodically poled grating periods of the crystal. The crystal has a plurality of segments associated with a plurality of grating periods of the output curve, each segment of the plurality of segments having a different crystal structure. At least one of the plurality of segments comprises a crystal structure combining at least two of the grating periods A heating device heats the crystal to an elevated operating temperature and is adjustable for adjusting the output wavelengths of each of the segments.

7. 发明申请

US20060172323A1 Identification of compounds that modify transcriptional responses to hypoxia 审中-公开
标题翻译：鉴定修饰缺氧转录反应的化合物
公开(公告)号：US20060172323A1
公开(公告)日：2006-08-03
申请号：US11261834
申请日：2005-10-28
申请人： David Livingston , Andrew Kung , Shoumo Bhattacharya
发明人： David Livingston , Andrew Kung , Shoumo Bhattacharya
IPC分类号： C12Q1/68 , G01N33/53 , A61K38/17
CPC分类号： G01N33/5023 , A61K49/0008
摘要： The invention provides methods for identifying compounds that can be used to modify transcriptional responses to hypoxia, and use of such compounds in therapeutic and diagnostic methods.
摘要翻译：本发明提供了用于鉴定可用于修饰对缺氧的转录反应的化合物的方法，以及在治疗和诊断方法中使用这些化合物。

8. 发明授权

US07892767B2 Phosphospecific chemokine receptor antibodies 有权
标题翻译：磷酸化趋化因子受体抗体
公开(公告)号：US07892767B2
公开(公告)日：2011-02-22
申请号：US11994048
申请日：2006-06-30
申请人： Joshua Rubin , Andrew Kung
发明人： Joshua Rubin , Andrew Kung
IPC分类号： G01N33/53 , G01N31/00
CPC分类号： C07K14/7158 , A61K2039/505 , C07K16/2866
摘要： The present invention provides chemokine receptor antibodies that selectively bind to an activated form of the receptor but not to a non activated form of the receptor. In particular, the current invention provides phosphospecific chemokine receptor antibodies. The antibodies can be used in several diagnostic, screening and purification methods.
摘要翻译：本发明提供趋化因子受体抗体，其选择性地结合受体的活化形式，但不与受体的非活化形式结合。特别地，本发明提供磷酸特异性趋化因子受体抗体。抗体可用于多种诊断，筛选和纯化方法。

9. 发明申请

US20170101688A1 NOL3 IS A PREDICTOR OF PATIENT OUTCOME 审中-公开
公开(公告)号：US20170101688A1
公开(公告)日：2017-04-13
申请号：US15373063
申请日：2016-12-08
申请人： Andrew Kung , David Ziegler
发明人： Andrew Kung , David Ziegler
IPC分类号： C12Q1/68 , A61K31/437 , G01N33/574 , A61K31/506
CPC分类号： C12Q1/6886 , A61K31/437 , A61K31/496 , A61K31/506 , A61K45/06 , C07D417/02 , C12Q2600/106 , C12Q2600/112 , C12Q2600/118 , C12Q2600/136 , C12Q2600/158 , G01N33/5044 , G01N33/57407 , G01N33/57484 , G01N2800/52 , G01N2800/7028 , A61K2300/00
摘要： The present invention features a method for determining the prognosis for survival of a cancer patient. Methods for measuring the level of NOL3 expression in a cancer cell-containing sample from a patient, and comparing the level of NOL3 expression in the sample to a reference level of NOL3 expression are also included. A higher level of NOL3 relative to the reference level correlates with decreased survival of the patient, and an equivalent or lower level of NOL3 relative to the reference level correlates with increased survival of the patient.

10. 发明申请

US20140357684A1 NOL3 IS A PREDICTOR OF PATIENT OUTCOME 有权
标题翻译： NOL3是患者的预测因素
公开(公告)号：US20140357684A1
公开(公告)日：2014-12-04
申请号：US14464394
申请日：2014-08-20
申请人： Andrew KUNG , David ZIEGLER
发明人： Andrew KUNG , David ZIEGLER
IPC分类号： C07D417/02 , G01N33/50
CPC分类号： C12Q1/6886 , A61K31/437 , A61K31/496 , A61K31/506 , A61K45/06 , C07D417/02 , C12Q2600/106 , C12Q2600/112 , C12Q2600/118 , C12Q2600/136 , C12Q2600/158 , G01N33/5044 , G01N33/57407 , G01N33/57484 , G01N2800/52 , G01N2800/7028 , A61K2300/00
摘要： The present invention features a method for determining the prognosis for survival of a cancer patient. Methods for measuring the level of NOL3 expression in a cancer cell-containing sample from a patient, and comparing the level of NOL3 expression in the sample to a reference level of NOL3 expression are also included. A higher level of NOL3 relative to the reference level correlates with decreased survival of the patient, and an equivalent or lower level of NOL3 relative to the reference level correlates with increased survival of the patient.
摘要翻译：本发明的特征在于确定癌症患者的存活预后的方法。还包括用于测量来自患者的含癌细胞的样品中的NOL3表达水平以及将样品中NOL3表达水平与NOL3表达的参考水平进行比较的方法。相对于参考水平的较高水平的NOL3与患者的生存率降低相关，并且相对于参考水平的等同或更低水平的NOL3与患者的增加的存活相关。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式